Clinical results with imatinib in chronic myeloid leukaemia.
Since its introduction 5 years ago, imatinib mesylate has shown remarkable efficacy in treating patients with chronic myeloid leukaemia. Here we shall review the clinical results seen with imatinib at all stages of the disease, current views on the best way to monitor patients' responses and potential ways of predicting response to treatment. We shall also briefly cover the reasons why quiescent stem cells pose a theoretical threat to successful treatment.
Crossman
Lucy C
LC
School of Clinical & Laboratory Sciences, University of Newcastle, Newcastle NE2 2HH, UK.
O'Brien
Stephen
S
D001549:Benzamides; D018572:Disease-Free Survival; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy*; D018365:Neoplasm, Residual / Q000175:diagnosis; D014411:Neoplastic Stem Cells / Q000187:drug effects; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate